Acute Pain Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight

(Albany, US) DelveInsight has launched a new report on “Acute Pain - Market Insights, Epidemiology, and Market Forecast-2030”.

DelveInsight's "Acute Pain - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Acute Pain, historical and forecasted epidemiology as well as the Acute Pain market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some facts of the report:

1.       The patient pool of Acute Pain in the 7MM countries was nearly 119,619,121 cases in 2017.

2.       As per estimates, the USA accounted for approximately 74.32% of total cases of Acute Pain, in the 7MM countries, in 2017.

3.       Among the EU-5 countries, Germany accounted for the highest number of cases for acute pain.

4.       Of the population undergoing surgery in the US, nearly 80% experienced acute postoperative pain, thereby contributing 41,766,061 patients to the Acute Pain population in 2017.

Key Benefits of the Report:

1.       Acute Pain Market report covers a descriptive overview and comprehensive insight of the Acute Pain epidemiology and Acute Pain market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

2.       Acute Pain market report provides insights on the current and emerging therapies.

3.       Acute Pain market report provides a global historical and forecasted market covering drug outreach in 7 MM.

4.       Acute Pain market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Acute Pain market.

Request for Sample Page: https://www.delveinsight.com/sample-request/acute-pain-market

View Report: https://www.delveinsight.com/report-store/acute-pain-market

Acute pain is defined as “an expected physiologic experience to injurious stimuli that can become pathologic, is normally sudden in onset, time-limited, and motivates behaviors to avoid actual or potential tissue injuries.”

The presence of pain often means that something is wrong. Each individual is the best judge of his or her own pain. There are different types of pain; basically, they are categorized into two forms, i.e., acute pain and chronic pain. Acute pain usually comes on suddenly and is caused by something specific. It is sharp in quality. Acute pain usually does not last longer than six months. It goes away when there is no longer an underlying cause for the pain.

On the other hand, chronic pain is pain that is ongoing and usually lasts longer than six months. This type of pain can continue even after the injury or illness that caused it has healed or gone away. Pain signals remain active in the nervous system for weeks, months, or years.

Since acute pain is a broad term, the symptoms associated with acute pain vary diversely. The most common symptoms that may be associated with acute pain include flu-like symptoms (fever, chills, sore throat, cough), fatigue, numbness, muscle spasms, insomnia, weight loss, anxiety, depression.

 

“The market size is expected to increase during the study period (2017–2030).”

View Report: https://www.delveinsight.com/report-store/acute-pain-market

Request for Sample Page: https://www.delveinsight.com/sample-request/acute-pain-market

 

The launch of the emerging therapies is expected to significantly impact Acute Pain treatment scenario in the upcoming years:-

Drugs covered:

·         Licart (Diclofenac Epolamine)

·         Dsuvia (Sufentanil)

·         Apadaz

·         Zalviso

·         Tivorbex (Indomenthacin)

·         Zorvolex (Diclofenac)

·         Oxecta

·         Exparel

·         Zipsor

·         Nucynta

·         Ofirmev

·         Ultracet

·         Ubrogepant

·         Oliceridine injection (TRV130)

·         HTX-011

·         CL-108

·         Dexketoprofen Tramadol

·         MR308

·         CR845

·         Capsaicin/Diclofenac

·         Ibuprofen

·         Methoxyflurane

·         CA-008

·         VX-150

·         CL-H1T

·         Tolperisone

·         NTM-001

The key players in Acute Pain market are:

·         IBSA Institut Biochimique SA/ Teikoku Seiyaku

·          AcelRx Pharmaceuticals

·          KemPharm

·          AcelRx Pharmaceuticals

·          Iroko Pharmaceuticals

·          EGALET

·          King Pharmaceuticals, Inc.

·          Pacira Pharmaceuticals

·          Depomed

·          Ortho-McNeil-Janssen

·          Mallinckrodt

·          Janssen Pharms

·          Allergan

·          Trevena

·          Heron Therapeutics

·          Charleston Laboratories

·          Menarini Group

·          Mundipharma Research GmbH & Co KG/Laboratorios del Dr Esteve, S.A.

·          Cara Therapeutics

·          Boehringer Ingelheim

·          Boehringer Ingelheim

·          Medical Developments International Limited

·          Concentric Analgesics

·          Vertex Pharmaceuticals Incorporated

·          Charleston Laboratories

·          Neurana Pharmaceuticals

·          Neumentum Pharmaceuticals

Request for Sample Page: https://www.delveinsight.com/sample-request/acute-pain-market

 View Report: https://www.delveinsight.com/report-store/acute-pain-market

Table of Contents:

1. Key Insights

2. Executive Summary of Acute Pain

3. Competitive Intelligence Analysis for Acute Pain

4. Acute Pain: Market Overview at a Glance

4.1. Acute Pain Total Market Share (%) Distribution in 2017

4.2. Acute Pain Total Market Share (%) Distribution in 2030

5. Acute Pain: Disease Background and Overview

5.1. Introduction

5.2. Sign and Symptoms 

5.3. Pathophysiology 

5.4. Risk Factors 

5.5. Diagnosis 

6. Patient Journey

7. Acute Pain Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. Epidemiology Scenario: 7MM

7.3.1. Acute Pain Epidemiology Scenario in the 7MM (2017-2030)

7.4. United States Epidemiology

7.4.1. Acute Pain Epidemiology Scenario in the United States (2017-2030)

7.5. EU-5 Country-wise Epidemiology

7.5.1. Germany Epidemiology

7.5.1.1. Acute Pain Epidemiology Scenario in Germany (2017-2030)

7.5.2. France Epidemiology

7.5.2.1. Acute Pain Epidemiology Scenario in France (2017-2030)

7.5.3. Italy Epidemiology

7.5.3.1. Acute Pain Epidemiology Scenario in Italy (2017-2030)

7.5.4. Spain Epidemiology

7.5.4.1. Acute Pain Epidemiology Scenario in Spain (2017-2030)

7.5.5. United Kingdom Epidemiology

7.5.5.1. Acute Pain Epidemiology Scenario in the United Kingdom (2017-2030)

7.5.6. Japan Epidemiology

7.5.6.1. Acute Pain Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Acute Pain Treatment and Management

8.2. Acute Pain Treatment Algorithm 

9. Unmet Needs

10. Key Endpoints of Acute Pain Treatment

11. Marketed Products

11.1. List of Marketed Products in the 7MM

11.2. Drug Name: Company Name

11.2.1. Product Description

11.2.2. Regulatory Milestones

11.2.3. Other Developmental Activities

11.2.4. Pivotal Clinical Trials

11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

12.1. Key Cross

12.2. Drug Name: Company Name

12.2.1. Product Description

12.2.2. Other Developmental Activities

12.2.3. Clinical Development

12.2.4. Safety and Efficacy

12.2.5. Product Profile

List to be continued in report

13. Acute Pain: Seven Major Market Analysis

13.1. Key Findings

13.2. Acute Pain Market Size in 7MM

13.3. Acute Pain Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

15.1. United States: Market Size

15.1.1. Acute Pain Total Market Size in the United States

15.1.2. Acute Pain Market Size by Therapies in the United States

15.2. EU-5 countries: Market Size and Outlook

15.3. Germany Market Size

15.3.1. Acute Pain Total Market Size in Germany

15.3.2. Acute Pain Market Size by Therapies in Germany

15.4. France Market Size

15.4.1. Acute Pain Total Market Size in France

15.4.2. Acute Pain Market Size by Therapies in France

15.5. Italy Market Size

15.5.1. Acute Pain Total Market Size in Italy

15.5.2. Acute Pain Market Size by Therapies in Italy

15.6. Spain Market Size

15.6.1. Acute Pain Total Market Size in Spain

15.6.2. Acute Pain Market Size by Therapies in Spain

15.7. United Kingdom Market Size

15.7.1. Acute Pain Total Market Size in the United Kingdom

15.7.2. Acute Pain Market Size by Therapies in the United Kingdom

15.8. Japan Market Outlook

15.8.1. Japan Market Size

15.8.2. Acute Pain Total Market Size in Japan

15.8.3. Acute Pain Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Acute Pain

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

Request for Detailed TOC : https://www.delveinsight.com/sample-request/acute-pain-market

 

Related Reports:

Acute Pain - Pipeline Insights, 2020

"Acute Pain Pipeline Insight, 2020" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Acute Pain market. A detailed picture of the Acute Pain pipeline landscape is provided, which includes the disease overview and Acute Pain treatment guidelines.

 

Acute Pain - Epidemiology Forecast to 2030

DelveInsight's 'Acute Pain - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Acute Pain epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

 

Comments

Post a Comment

Popular posts from this blog

How Competitive intelligence is transforming the scenario for Biotech firms?

What is Competitive intelligence service? Competitive intelligence ideally means gathering information on rival business in the market, analyse the information and use the information to strategize to yield positive results. Going by the definition, competitive intelligence assembles actionable information from diverse published and unpublished sources, collected efficiently and ethically. So, analysts performing Competitive intelligence for their clienteles present a detailed picture of the marketplace, forthcoming challenges and the ways to face them, even before the can harm the client’s business. What could it mean? Competitive intelligence can often give a wrong idea, as it may misunderstood as a service which can help gain an advantage over the rivals. However, this is not the case. Competitive intelligence is an ethical and legal practise undertaken involving the study of analytical data, analysing the market and optimizing the relevant and realistic strategies t...
Read more

The Need And The Importance Of The Healthcare Reports for the Pharma Companies

Image
It is very important for the hospitals and the other medical institutions to preserve and keep the healthcare reports of all the patients very safe and secure. All the medical records are being kept by almost all of these institutes. As a matter of fact, the healthcare reports are very important for comprehending the medical history of the patient. If he or she suffers from the same ailment once more the previous reports will be absolutely indispensible while treating him or her. Nowadays, with the advancement of technology the manual records are slowly and gradually getting digitalized. It is easier to store and preserve the digital records than the manual and the physical ones.  Choosing The Best And The Most Professional Services For Healthcare Reports: • Rising Pharma Market for You Now In the market there are a host of companies that preserves the healthcare reports of the various patients. All of it is now being done in the digital format due to the adv...
Read more

Vernal Keratoconjunctivitis Market

(Albany, US) DelveInsight’s “ Vernal Keratoconjunctivitis Market  Insights, Epidemiology, and Market Forecast-2030 ” report provides an in-depth understanding of the disease, historical and forecasted epidemiology, as well as Vernal Keratoconjunctivitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Some of the key facts of the  Vernal Keratoconjunctivitis Market The increasing population and rising prevalence of Vernal Keratoconjunctivitis generates a large patient population in the global market. In 2017, a total of 4,752,356 patients were affected by Vernal Keratoconjunctivitis in the global market. China contributes the largest share among EU-5, and Japan, with 2,248,706 cases in 2017. The total diagnosed prevalent population of Vernal Keratoconjunctivitis was 2,943,057 in the global market.   Request for Sample Report: https://www.delveinsight.com/report-store...
Read more